The oncolytic virus therapy-based cancer drug developer raised $77m in a GV-backed series A round as it prepares to file an IND application next year.
GV, a corporate venturing subsidiary of internet and technology conglomerate Alphabet, took part in a $77m series A round for US-based oncology therapy developer IconOVir Bio today.
Venture capital firm Nextech and life sciences investment firm Vida Ventures co-led the round, which included VC firm Two River Group, Bellco Capital, Polaris Partners, Wellington Partners Venture Capital and Logos Capital.
Founded by Two River Group, IconOVir is developing oncolytic virus therapies that will form the basis of personalised cancer treatments. It…
